These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
25. [Metastatic melanoma: some hope from ipilimumab and vemurafenib]. Piérard-Franchimont C; Piérard GE Rev Med Liege; 2012 Feb; 67(2):64-8. PubMed ID: 22482234 [TBL] [Abstract][Full Text] [Related]
26. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Majer M; Jensen RL; Shrieve DC; Watson GA; Wang M; Leachman SA; Boucher KM; Samlowski WE Cancer; 2007 Sep; 110(6):1329-37. PubMed ID: 17623835 [TBL] [Abstract][Full Text] [Related]
27. Narrowing the knowledge gaps for melanoma. Slipicevic A; Herlyn M Ups J Med Sci; 2012 May; 117(2):237-43. PubMed ID: 22339359 [TBL] [Abstract][Full Text] [Related]
28. Vemurafenib: a guide to its use in unresectable or metastatic melanoma. Keating GM; Lyseng-Williamson KA Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082 [TBL] [Abstract][Full Text] [Related]
31. Current advances and perspectives in the treatment of advanced melanoma. Livingstone E; Zimmer L; Vaubel J; Schadendorf D J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863 [TBL] [Abstract][Full Text] [Related]
32. [Major therapeutic advances in the treatment of metastatic melanoma]. Mateus C; Robert C Bull Cancer; 2012 Jun; 99(6):619-25. PubMed ID: 22652330 [TBL] [Abstract][Full Text] [Related]
33. The role of radiotherapy in the overall treatment of melanoma. Forschner A; Heinrich V; Pflugfelder A; Meier F; Garbe C Clin Dermatol; 2013; 31(3):282-9. PubMed ID: 23608447 [TBL] [Abstract][Full Text] [Related]
34. Vemurafenib as a neoadjuvant therapy in advanced melanoma: local tumour control, but no prevention of metastatic relapse. Tauber M; Pages C; La Selva R; Schneider P; Chardin J; Osio A; Mourah S; Culine S; Vercellino L; Bagot M; Lebbé C Eur J Dermatol; 2013; 23(5):702-3. PubMed ID: 24135270 [No Abstract] [Full Text] [Related]
35. [New paradigms and metaphors in cutaneous melanoma treatment]. Piérard GE; Nizet JL; Humbert P Rev Med Liege; 2016 Dec; 71(12):562-566. PubMed ID: 28387097 [TBL] [Abstract][Full Text] [Related]
37. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Miller DM; Flaherty KT; Tsao H Semin Cutan Med Surg; 2014 Jun; 33(2):60-7. PubMed ID: 25085663 [TBL] [Abstract][Full Text] [Related]
38. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report. Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086 [TBL] [Abstract][Full Text] [Related]
39. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
40. [Advances in clinical treatment of malignant melanoma: B-RAF kinase inhibition]. Heneberg P Klin Onkol; 2011; 24(4):256-64. PubMed ID: 21905615 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]